Maze Therapeutics (MAZE) Assets (2024 - 2026)

Maze Therapeutics has disclosed Assets across 3 years of filings, most recently posting $419.7 million for Q1 2026.

• Assets for Q1 2026 came in at $419.7 million, up 26.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $419.7 million (up 26.1% YoY), and the FY2025 annual result was $397.1 million, up 65.1% from the prior year.
• Assets came in at $419.7 million for Q1 2026 at Maze Therapeutics, up from $397.1 million in the prior quarter.
• In the past five years, Assets ranged from a high of $422.1 million in Q3 2025 to a low of $240.5 million in Q4 2024.
• The 3-year median for Assets is $365.0 million (2025), against an average of $352.6 million.
• Across the five-year window, Assets surged 65.1% in 2025 and advanced 26.1% in 2026, its largest moves.
• Maze Therapeutics' Assets stood at $240.5 million in 2024, then soared by 65.1% to $397.1 million in 2025, then rose by 5.69% to $419.7 million in 2026.
• The last three Assets figures came in at $419.7 million (Q1 2026), $397.1 million (Q4 2025), and $422.1 million (Q3 2025), per Business Quant data.